Below are articles from various sources about members of MCB and their research.
Professor (Affiliated) of Genetics, Genomics and Development Steve Brenner heads up a portion of a five-year research program that may deeply influence how states use a heel prick, the first step in newborn screening. Most state public health departments check the infant’s blood after the first day of life to see if something is dangerously wrong. However, as genome sequencing becomes faster and cheaper, the push is on to unravel a baby’s entire DNA code instead.
Recent findings by Professor of Cell and Developmental Biology David Bilder and his lab could lead to the development of much-needed targeted therapies for wasting syndrome in cancer patients (this syndrome is called cachexia, where muscle and fat tissues are destroyed throughout the body).
A newly announced biotech deal shows how basic research at UC Berkeley is leading to new therapeutic approaches for cancer.
Professor Jennifer Doudna and other leading bioligists authored an article calling for a worldwide moratorium on the use of her new genome-editing technique until scientists, ethicists and the public fully understand the issues surrounding the breakthrough.
Professors Jennifer Doudna (MCB) and Montgomery Slatkin (IB), were chosen for their distinguished research excellence by the Academic Senate, and will present public lectures as part of the Martin Meyerson Faculty Research Lectures. Since 1912, these events have offered an opportunity to hear from the people who are transforming knowledge at Berkeley and in our world.
Assistant Professor of Biochemistry, Biophysics and Structural Biology and Bakar Fellow Andreas Martin is launching a search for small-molecule drugs to block the ability of cancer cells to rid themselves of proteins. Doing so would overwhelm the cells with excess baggage and kill them. A successful drug would also expose cancer cells to tumor-suppressor proteins, which prevent rampant division.